ATMA Submits N500 MDMA Phase II Clinical Trial Application to Health Canada

Posted on by

Designed to mirror ATMA’s Health Canada approved N500 Phase II Psilocybin Clinical Trial for frontline healthcare professionals CALGARY, AB, April 13, 2023 /PRNewswire/ – ATMA Journey Centers Inc. (“ATMA”), Canada’s leading psychedelic-assisted therapy training provider, is pleased to…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.